Beijing Zhivito Pharmaceutical Technology Co., Ltd. has recently declared the successful closure of its seed round financing, amassing tens of millions of yuan. This financing endeavor was spearheaded by Niulili Capital, with Qingtan Investment joining in as a co-investor. The proceeds from this round will be predominantly allocated to propel the preclinical development of the company's key drug candidates and to establish an AI-interactive molecular design platform.

Established in 2024 by Dr. Long Wei, Zhivito Pharmaceuticals embraces a research and development approach that harmoniously blends artificial intelligence with expert insights, with a keen focus on pioneering oral medications. Dr. Long Wei remarked that this infusion of funds would enable the company to forge ahead with clinical trials for its primary drug candidates and to further refine the AI-interactive molecular design platform.

The investors conveyed their confidence in Zhivito Pharmaceuticals' strategic vision, innovative prowess, and potential within the autoimmune disease sector, eagerly anticipating further strides in its research and development pursuits.